Targeting ATP2B1 impairs PI3K/Akt/FOXO signaling and reduces SARS-COV-2 infection and replication.
de Antonellis P, Ferrucci V, Miceli M, Bibbo F, Asadzadeh F, Gorini F, Mattivi A, Boccia A, Russo R, Andolfo I, Lasorsa VA, Cantalupo S, Fusco G, Viscardi M, Brandi S, Cerino P, Monaco V, Choi DR, Cheong JH, Iolascon A, Amente S, Monti M, Fava LL, Capasso M, Kim HY, Zollo M.
de Antonellis P, et al. Among authors: ferrucci v.
EMBO Rep. 2024 Jul;25(7):2974-3007. doi: 10.1038/s44319-024-00164-z. Epub 2024 May 30.
EMBO Rep. 2024.
PMID: 38816514
Free PMC article.